Compare PSN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSN | GRFS |
|---|---|---|
| Founded | 1944 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.4B |
| IPO Year | 2019 | N/A |
| Metric | PSN | GRFS |
|---|---|---|
| Price | $53.67 | $7.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 2 |
| Target Price | ★ $79.18 | $10.15 |
| AVG Volume (30 Days) | ★ 1.3M | 589.6K |
| Earning Date | 04-29-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | ★ 3.77 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $6,364,245,000.00 | N/A |
| Revenue This Year | $5.87 | $4.49 |
| Revenue Next Year | $7.61 | $6.42 |
| P/E Ratio | $105.76 | ★ $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $48.23 | $7.39 |
| 52 Week High | $89.50 | $11.14 |
| Indicator | PSN | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 55.20 | 48.45 |
| Support Level | $48.81 | $7.87 |
| Resistance Level | $66.57 | $9.78 |
| Average True Range (ATR) | 2.14 | 0.21 |
| MACD | 0.48 | 0.02 |
| Stochastic Oscillator | 98.91 | 50.26 |
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe. The company derives maximum revenue from Federal Solutions segment. Geographically, the company derives revenue from North America; Middle East; and Rest of the World, of which North America derives maximum revenue.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.